Brief: Infinity Receives Fast Track Designation For IPI-549 In Combination With The Checkpoint Inhibitor Opdivo For The Treatment Of Advanced Urothelial Cancer
25/03/2020 11:41
March 25 (Reuters) - Infinity Pharmaceuticals Inc INFI.O :
* INFINITY RECEIVES FAST TRACK DESIGNATION FOR IPI-549 IN
COMBINATION WITH THE CHECKPOINT INHIBITOR OPDIVO FOR THE
TREATMENT OF ADVANCED UROTHELIAL CANCER
* INFINITY PHARMACEUTICALS INC - CURRENTLY ENROLLING
PATIENTS IN
MARIO-275 TO EVALUATE IPI-549 IN COMBINATION WITH OPDIVO
Source text for Eikon: ID:nBwb2lV7sa
Further company coverage: INFI.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Infinity Pharmaceuticals
See all newsBrief: Infinity Pharmaceuticals Filed Voluntary Petition For Relief Under Provisions Of Chapter 11
Brief: Infinity Pharmaceuticals Inc Received Determination Letter From Nasdaq On September 12
Brief: Infinity Pharma Says On Sept 5, 2023, Co Received Letter From Nasdaq Notifying That Listing Of Common Stock Was Not In Compliance With Nasdaq Listing Rule
Brief: Infinity Pharmaceuticals Approved Plan To Reduce Co's Overall Headcount By 21 Positions
U.S. STOCKS ON THE MOVE-General Motors, Estee Lauder, IMAX